MoonLake Immunotherapeutics announced a positive outcome from its final pre-BLA meeting with the U.S. FDA, agreeing on submission plans and labeling strategy for sonelokimab in treating hidradenitis suppurativa (HS). The FDA accepted key clinical trial data, including adolescent patient data, with no remaining gaps identified, enabling a planned BLA submission by the end of September 2026 and potential Priority Review by November 2026. MoonLake ended Q1 2026 with $357.9 million in cash and expects to fund operations through 2027. Upcoming milestones include further clinical trial data releases and the anticipated commercial launch in the U.S. in the second half of 2027.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
